《大行報告》中金首予亞盛醫藥-B(06855.HK)「跑贏行業」評級 目標價60元
中金發表研究報告,首次覆蓋亞盛醫藥-B(06855.HK)予「跑贏行業」評級,目標價60元。該行指,公司為專注於細胞凋亡創新藥物,科學驅動研發型生物科技企業,其有望通過其差異化的產品以及中美同時開發的臨床策略,能夠更快地將公司的潛力新型原創小分子藥物推向全球市場,國際化潛力出眾。
報告稱,其後期臨床階段候選藥物市場前景廣闊,已建立了豐富且差異化的研發管線。該行料其2021及2022年每股虧損分別3.9元及1.51元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.